Pharma BD Deal Intelligence
Valeant's $8.7 billion deal for Bausch & Lomb, the eye-care company owned by Warburg Pincus, positions Canada's largest drugmaker to compete globally in the…
Warburg Pincus roughly tripled its 2007 take-private investment; Valeant CEO Pearson framed the deal as putting Valeant 'among the 15 largest global…
Three years on, the B+L unit was the best-performing asset Valeant owned and arguably the only piece worth the original price — a retroactive vindication of…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Valeant agreed to acquire Bausch + Lomb from Warburg Pincus-led group for $8.7B cash ($4.5B to investors, $4.2B to repay B+L debt); created global eye-health platform with pro-forma 2013 net revenue >$3.5B.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb (this deal) | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation | 2012 | $2.6B | 33 |
| Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. | 2014 | $475M | 23 |
← Browse all deals · How we score deals
More: 2013 deals · Valeant Pharmaceuticals International, Inc. deals · Ophthalmology deals